Date published: 2025-10-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

SLC35D2 Activators

Forskolin engages directly with adenylyl cyclase to elevate intracellular cAMP, leading to the activation of protein kinase A (PKA). The heightened activity of PKA might enhance the phosphorylation of numerous proteins, including SLC35D2, which in turn can alter its functionality. IBMX works synergistically with forskolin by inhibiting phosphodiesterases, thereby sustaining increased levels of cAMP and supporting the PKA-mediated phosphorylation state of proteins. PMA is another activator that targets protein kinase C (PKC), a kinase that can phosphorylate a wide spectrum of proteins. Through its action, PMA may indirectly influence the activity of SLC35D2 by altering the phosphorylation landscape within the cell. Similarly, Epidermal Growth Factor (EGF) engages with its receptor to activate the MAPK/ERK signaling pathway, which is crucial for the regulation of protein function via phosphorylation, potentially affecting SLC35D2 activity.

The modulation of intracellular calcium levels is another vector through which SLC35D2 activity can be influenced. Ionomycin, by increasing intracellular calcium, and thapsigargin, by inhibiting the calcium ATPase SERCA, both elevate cytosolic calcium, which could activate calcium/calmodulin-dependent protein kinases that may target SLC35D2. Okadaic Acid and Calyculin A inhibit protein phosphatases such as PP1 and PP2A, which normally dephosphorylate proteins. Their inhibition thereby maintains proteins in a phosphorylated state, indirectly supporting the active state of SLC35D2. Genistein, as a tyrosine kinase inhibitor, LY294002, as a PI3K inhibitor, and Rapamycin, an mTOR inhibitor, all modulate various signaling pathways that could intersect with the regulation of SLC35D2. MG132, a proteasome inhibitor, can lead to the accumulation of proteins including ubiquitinated proteins which might affect SLC35D2 stability or its function.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$76.00
$150.00
$725.00
$1385.00
$2050.00
73
(3)

Forskolin directly stimulates adenylyl cyclase, increasing cAMP levels and activating PKA, which can enhance the phosphorylation state of proteins, potentially including SLC35D2.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$159.00
$315.00
$598.00
34
(1)

IBMX inhibits phosphodiesterases, leading to increased cAMP levels, which can sustain the activation of PKA and indirectly maintain SLC35D2 in an active phosphorylation state.

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$40.00
$129.00
$210.00
$490.00
$929.00
119
(6)

PMA activates PKC, which can phosphorylate a broad range of cellular proteins, potentially including SLC35D2, altering its activity.

Ionomycin

56092-82-1sc-3592
sc-3592A
1 mg
5 mg
$76.00
$265.00
80
(4)

Ionomycin increases intracellular calcium levels, which can activate CaMKs that may phosphorylate and modulate SLC35D2.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$94.00
$349.00
114
(2)

By inhibiting SERCA, thapsigargin raises cytosolic calcium levels, potentially leading to the activation of CaMKs and modulation of SLC35D2.

Okadaic Acid

78111-17-8sc-3513
sc-3513A
sc-3513B
25 µg
100 µg
1 mg
$285.00
$520.00
$1300.00
78
(4)

Okadaic Acid inhibits PP1 and PP2A, preventing dephosphorylation and thus maintaining proteins, including SLC35D2, in an active state.

Calyculin A

101932-71-2sc-24000
sc-24000A
sc-24000B
sc-24000C
10 µg
100 µg
500 µg
1 mg
$160.00
$750.00
$1400.00
$3000.00
59
(3)

Similar to Okadaic Acid, Calyculin A inhibits protein phosphatases PP1 and PP2A, stabilizing the phosphorylation status of SLC35D2.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$26.00
$92.00
$120.00
$310.00
$500.00
$908.00
$1821.00
46
(1)

Genistein is a tyrosine kinase inhibitor that can modulate various signaling pathways, potentially influencing the phosphorylation and activity of SLC35D2.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

As a PI3K inhibitor, LY294002 can alter AKT signaling, which may indirectly influence the function of SLC35D2.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin inhibits mTOR, which affects several downstream signaling pathways, possibly including those regulating SLC35D2.